HMGA2 and breast cancer: More importantly, our results give a better understanding of the roles of METTL3 and m6A in BC, and may present a range of new therapeutic targets involving METTL3, MALAT1, miR-26b and HMGA2, especially for the treatment for triple-negative cancer.